Caxton Associates (UK)’s Ingevity NGVT Stock Holding History

Caxton Associates (UK)’s Portfolio NGVT Stock Details NGVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,999	Closed	-$237K	–	932
2025 Q4	$237K	Buy	+3,999	New	+$217K	﹤0.01%	678

Other funds holding NGVT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

SCM

Simcoe Capital Management New York $576M AUM 36.22% 1-Year Est. Return

Caxton Associates (UK)'s NGVT Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Ingevity (NGVT) in Q1 2026, closing a stake of 3,999 shares — an estimated $237K sold.

Caxton Associates (UK) first reported a position in NGVT in Q4 2025 and held it in 1 quarter. The position peaked at $237K in Q4 2025. 307 funds tracked by Wall St. Rank hold NGVT as of Q1 2026.

Caxton Associates (UK) reported no remaining Ingevity position as of Q1 2026 after selling out during the quarter.
Caxton Associates (UK) sold 3,999 Ingevity shares in Q1 2026, an estimated $237K.
Caxton Associates (UK) first reported a position in Ingevity in Q4 2025 and held it in 1 quarter.
Caxton Associates (UK)'s Ingevity position peaked at $237K in Q4 2025.
307 funds tracked by Wall St. Rank held Ingevity as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.